Tourmaline Bio, INC Form 4 insider transactions

Ryan F. Robinson, CFO of Tourmaline Bio, Inc., reports the acquisition of 76,400 employee stock options on June 25, 2024.

Clay B. Siegall, a director at Tourmaline Bio, Inc., acquired 15,000 stock options on June 5, 2024, at an exercise price of $13.91.

Mark McDade, a director of Tourmaline Bio, Inc., acquired stock options for 10,000 shares on June 5, 2024.

Director Aaron Kantoff acquired stock options in Tourmaline Bio, Inc. on June 5, 2024.

Director Sapna Srivastava acquired stock options for 10,000 shares of Tourmaline Bio, Inc. at an exercise price of $13.91 on June 5, 2024.

Director Parvinder Thiara acquired 10,000 stock options in Tourmaline Bio, Inc. on June 5, 2024, at an exercise price of $13.91.

Director Caley Castelein of Tourmaline Bio, Inc. reports the acquisition of stock options.